Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-03
2008-12-23
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S156000
Reexamination Certificate
active
07468378
ABSTRACT:
This invention relates to MTP/Apo-B secretion inhibitors of Formula (I)wherein R1—R7, X1, m and n are as defined in the specification, as well as pharmaceutical compositions comprising the compounds, and methods of use of the compounds and compositions. The compounds of the invention are useful in treating obesity and associated diseases, conditions or disorders.
REFERENCES:
patent: 5712279 (1998-01-01), Biller et al.
patent: 5804588 (1998-09-01), Dyke et al.
patent: 5919795 (1999-07-01), Chang et al.
patent: 5968950 (1999-10-01), Quallich et al.
patent: 6066653 (2000-05-01), Gregg et al.
patent: 6093732 (2000-07-01), Tucker et al.
patent: 6121282 (2000-09-01), Dominianni et al.
patent: 6369075 (2002-04-01), Ruggeri et al.
patent: 6492365 (2002-12-01), Wetterau et al.
patent: 2002/0032238 (2002-03-01), Priepke et al.
patent: 2002/0042516 (2002-04-01), Tom et al.
patent: 2003/0162788 (2003-08-01), Thomas et al.
patent: 2006/0223851 (2006-10-01), Bertinato et al.
patent: 2007/0093525 (2007-04-01), Bertinato et al.
patent: 0059983 (1986-06-01), None
patent: 0643057 (1994-09-01), None
patent: 1099438 (2001-05-01), None
patent: 1099701 (2001-05-01), None
patent: 0584446 (2002-06-01), None
patent: 1447402 (2004-08-01), None
patent: WO95/32948 (1995-12-01), None
patent: WO96/040640 (1996-12-01), None
patent: WO9640640 (1996-12-01), None
patent: WO9743257 (1997-11-01), None
patent: WO9827979 (1998-07-01), None
patent: WO99/14196 (1999-03-01), None
patent: WO0005201 (2000-02-01), None
patent: WO0228835 (2002-04-01), None
patent: WO03002533 (2003-01-01), None
patent: WO03035624 (2003-05-01), None
patent: WO03072532 (2003-09-01), None
patent: WO2004056775 (2004-07-01), None
US5804588 equivalent to RU98123074.
US6093732 equivalent to RU2220960.
WO03/035,624 is the Japanese language equivalent of EP1447402.
Jensen, A.E., et al., Improved nickel-catalyzed cross-coupling reaction conditions between ortho-substituted aryl iodides
onaflates and alkylzinc iodides in solution and in the solid-phase,Tetrahedron, vol. 56: 4197-4201, 2000.
Mathias, L.J., Esterification and alkylation reactions employing isoureas,Synthesis, 561-576, 1979.
Wetterau, J.R., et al., Localization of intracellular triacylglycerol and cholesteryl ester transfer activity in rat tissues,Biochimica et Biophysica Acta, vol. 875: 61-617, 1986.
Wetterau, J.R., et al., Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia,Science, vol. 258: 999-1001, 1992.
WO 99/14196 equivalent to EA 002633B1.
WO 96/040640 equivalent to RU 96111018.
WO 95/32948 equivalent to RU2155754.
Bertinato Peter
Couturier Michel A.
Ewing Marcus D.
Hamanaka Ernest S.
Robinson Ralph P.
Benson Gregg C.
Kennedy Robert M.
Pfizer Inc.
Seaman D. Margaret
LandOfFree
Substituted quinoline compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted quinoline compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted quinoline compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4022157